Perioperative medicine & outcomes
Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial
Authors' conclusion
In this randomized clinical trial, once-daily VTE prophylaxis with 10 mg of rivaroxaban was effective and safe in the early postoperative phase after bariatric surgery in both the short and long prophylaxis groups.
Study context
- Population
- Patients after bariatric surgery at 3 academic and nonacademic hospitals in Switzerland, 2018–2021randomized of 300
- Participants
- 272 patients
- Comparison
- Rivaroxaban 10 mg/d for 28 days vs 7 days after bariatric surgery
- Short prophylaxisn = 134reference
- Long prophylaxisn = 135
- Primary endpoint
- Composite of:
- DVT (symptomatic or asymptomatic)
- PE
- Follow-up
- 28 days after bariatric surgery
Methodological detailsassessor-blinded, phase 2, multicentre
- Assessor-blinded
- Phase 2
- Multicentre
Primary result
As reported in the abstract
Venous thromboembolism (VTE) (DVT or PE) · 28 days
Only 1 thromboembolic event overall (asymptomatic thrombosis, sleeve gastrectomy, extended prophylaxis)
1
0.4%
Safety
Events
| Outcome | Short prophylaxis | Long prophylaxis |
|---|---|---|
| Major or clinically relevant nonmajor bleeding | 2 | 3 |
| Clinically nonsignificant bleeding | 3 | 7 |
- Major or clinically relevant nonmajor bleeding — Overall
- 5 (1.9%)
- Clinically nonsignificant bleeding — Overall
- 10 (3.7%)
Original publication
Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial. JAMA Netw Open. Published 1 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →